DoW Peer Reviewed Medical, Platform Clinical Translation Award
Closed Posted
- Opportunity number
- HT942526PRMRPPCTA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement, Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command is soliciting applications for the Fiscal Year 2026 Peer Reviewed Medical Research Program Platform Clinical Translation Award, with a full application deadline of September 22, 2026, and a pre-application deadline of July 23, 2026. The program expects to allot approximately $30 million to fund approximately two awards with total cost caps of $15 million per award.
Eligible applicants include extramural and intramural U.S. Department of War organizations, both for-profit and nonprofit. Independent investigators at the Assistant Professor level or equivalent may serve as Principal Investigators. The funding opportunity permits multiple Principal Investigators, with one identified as the Initiating PI and up to two additional Partnering PIs; if recommended for funding, each PI will be named on separate awards to the recipient organization(s).
Applicants must establish a PI-convened external advisory board with mandatory patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.
The maximum period of performance is four years. Awards will be funded with a maximum of $8 million in FY26, with remaining budget contingent on meeting performance-based milestones and availability of future funds expiring September 30, 2032. Awards will be made no later than September 30, 2027.
The award supports translational development and early-phase clinical trials for broadly applicable platform products addressing two congressionally directed FY26 PRMRP topic areas relevant to military Service Members, Veterans, and their families. Applications must demonstrate preliminary data showing product readiness for clinical translation and propose milestone-driven research with clear implementation plans. Direct costs prohibit tuition charges but allow travel for multi-institutional collaboration and research participant compensation.
The Assistance Listing number is 12.420 (Military Medical Research and Development). Peer review is scheduled for November/December 2026, followed by programmatic review in February/March 2027.
Synopsis
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.
Distinctive Features:
Allows for multiple Principal Investigators (PIs). The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).
Requires a PI-convened external advisory board with patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $30M to fund approximately two Platform Clinical Translation Award applications with total cost caps of $15M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with a maximum of $8M in FY26, with the remaining budget to be funded out of future fiscal years depending upon meeting performance-based milestones and availability of future funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Files
| File | Type | Posted |
|---|---|---|
| PKG00292732.pdf | ||
| HT942526PRMRPPCTA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity